Innovation Corps (I-Corps™) at NIH Program for NIH and CDC Translational Research (Admin Supp - Clinical Trial Not Allowed)

Funding Agency:
National Institutes of Health

Through this 'I-Corps™ at NIH' program Funding Opportunity Announcement (FOA), the National Institutes of Health and Center for Disease Control and Prevention (CDC) provide administrative supplement awards to active SBIR (NIH and CDC) and STTR Phase I (NIH only) recipients. The I-Corps at NIH program is focused on educating researchers and technologists on how to translate technologies from the lab into the marketplace. I-Corps enables and accelerates the transformation of invention to impact patients.

The program provides three-member project teams with access to instruction and mentoring to accelerate the translation of technologies currently being developed with NIH and CDC SBIR and STTR funding. The participants conduct evidence-based research to identify where the company's technology can have greatest impact on unmet clinical needs. It is anticipated that outcomes for the I-Corps teams participating in this program will include significantly refined commercialization plans and well-informed pivots in their overall commercialization strategies. Prospective applicants are strongly encouraged to contact relevant Scientific/Research staff  listed in Section VII for more information about the program before applying.  

Application Due Date(s): December 15, 2021; February 2, 2022; November 15, 2022; February 2, 2023; November 15, 2023; January 31, 2024; April 30, 2024

PAR-22-073 Expiration Date New Date May 1, 2024 (Original Date: February 3, 2024) per issuance of NOT-OD-23-188

Agency Website

Eligibility Requirements

Only United States small business concerns (SBCs) are eligible to submit applications for this opportunity.

IMPORTANT: The research proposed by the NIH grantee in the supplement application must be within the original scope of the NIH-supported grant project.

This announcement is for supplements to existing projects. To be eligible, the parent award must be active, and the research proposed in the supplement must be accomplished within the competitive segment. The proposed supplement must be to provide for an increase in costs due to unforeseen circumstances. All additional costs must be within the scope of the peer reviewed and approved project.

Only one supplement application per parent SBIR/STTR Phase I award is allowed under this FOA. Applicant organizations with multiple, currently-active SBIR and/or STTR Phase I awards from the different participating Institutes and Centers listed on this FOA may choose only ONE award to serve as the predicate for an administrative supplement to support the I-Corps at NIH program activity. The NIH and CDC will not fund multiple administrative supplement awards to the same applicant organization under this FOA.



        Amount Description

        Application budgets are limited to no more than $55,000 in total direct costs and must reflect the actual needs of the proposed project. Note in Section IV.2 that proposed budgets should also include $22,000 per team to cover workshop registration fees ($22,000 out of the total budget allowed of $55,000).

        Remaining budget should be allocated to cover travel costs to conduct on-site customer development interviews and personnel time for the I-Corps team members, as appropriate.

        No indirect costs should be requested.

        The funding mechanism being used to support this program, administrative supplements, can be used to cover cost increases that are associated with achieving certain new research objectives, as long as the research objectives are within the original scope of the peer reviewed and approved project, or the cost increases are for unanticipated expenses within the original scope of the project. Any cost increases need to result from making modifications to the project that would increase or preserve the overall impact of the project consistent with its originally approved objectives and purposes.

        Funding Type





        Medical - Translational

        External Deadline

        April 30, 2024